ARQT News and Press, Arcutis Biotherapeutics Inc. From 07/13/20

ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitors Company expects topline data in the second half of 2021 WESTLAKE VILLAGE, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (...

MyoKardia Reports Upbeat Phase 2a Clinical Data MyoKardia Inc. ( MYOK ) announced that its Phase 2a clinical trial of danicamtiv has yielded positive results. The company also discussed nonclinical data showing the novel mechanism of action of the drug candidate. Danicamtiv is MyoKar...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

Arcutis Biotherapeutics ( ARQT +3.4% ) has completed enrollment of its Phase 2 proof of concept clinical trial evaluating roflumilast foam as a potential treatment for seborrheic dermatitis , a chronic or recurrent skin condition that causes red patches and persistent itch. M...

Roflumilast foam potential “Best in Class” topical PDE4 inhibitor in foam formulation Seborrheic dermatitis affects over 6 million U.S. patients Phase 2 topline data anticipated early in fourth quarter of 2020 The Company also announced first patient enrolled in long-term...

WESTLAKE VILLAGE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermat...

WESTLAKE VILLAGE, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermat...

WESTLAKE VILLAGE, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermato...

Arcutis Biotherapeutics (NASDAQ: ARQT ): Q1 GAAP EPS of -$1.15 misses by $0.29 . More news on: Arcutis Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Multiple important Phase 3 and Phase 2 data events anticipated during 2020/2021 Arcutis currently expects no impact to its previously disclosed clinical timelines due to COVID-19 Strong financial position with $249.3 million in cash, cash equivalents and marketable securities WESTLAKE...